We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Nanoparticles plus Light Results in Dead Tumor Cells

By LabMedica International staff writers
Posted on 05 Sep 2008
Medical physicists have created a novel way to kill tumor cells using nanoparticles and light. More...
The technique employs quantum dots, which are semiconductor nanostructures, 25 billionths of a meter in diameter, which can confine electrons in three dimensions (3D) and emit light when exposed to ultraviolet radiation.

The technique was devised by Dr. Wensha Yang, an instructor in radiation oncology at the University of Virginia (Charlottesville, VA, USA), and colleagues. The investigators realized that quantum dots also emitted light when exposed to megavoltage X-rays, such as those used in cancer radiotherapy. That characteristic, the scientists realized, makes quantum dots an ideal mediator in therapies employing light-activated compounds to treat cancer.

A compound called Photofrin is the only photosensitizer currently approved by the U.S. Food and Drug Administration (FDA). Photofrin is absorbed by cancer cells, upon exposure to light, becomes active, and kills cells. It is currently used to treat specific types of shallowly located tumors, but the researchers realized that combing Photofrin with quantum dots could create an effective method to destroy even deeply seated cancer cells. Upon exposure to high doses of radiation, the dots become luminescent and emit light; that light triggers the cancer-killing activity of the Photofrin. In theory, the process, which so far has been evaluated only in cancer cells grown in culture, could work on tumors located too deep within the body to be reached by an external light source.

To prevent healthy tissues from being affected by the treatment, the toxicity of the quantum dot-Photofrin conjugate is only activated when radiation is applied. Moreover, the area to be treated is targeted with conformal radiation, which is delivered with high precision within the 3D contours of the tumor, with minimal spillover to surrounding healthy tissues. As a result, Dr. Yang said, "the toxicity of the drug is substantially lower in the lower radiation dose area,” outside the boundaries of the tumor. In studies on human lung carcinoma cells, the process resulted in a two to six times lower tumor cell survival compared to radiation alone, but with minimal toxicity to nearby cells.

Dr. Yang described the technique on July 29, 2008, during the 50th annual meeting of the American Association of Physicists in Medicine (AAPM), held, in Houston, TX, USA.

Related Links:
University of Virginia


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.